ClinicalTrials.Veeva

Menu
G

Grace Research, LLC | Shreveport, LA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Empagliflozin
BI 456906
TQJ230
BI 690517
Survodutide
Triglyceride
Lorundrostat
Obicetrapib
sodium
Bococizumab

Parent organization

This site is a part of Grace Research, LLC

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 14 total trials

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left...

Enrolling
Heart Failure
Drug: Empagliflozin
Drug: BI 690517

This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and eleva...

Active, not recruiting
Cardiovascular Disease and Lipoprotein(a)
Drug: TQJ230
Drug: Placebo

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting
Coronary Heart Disease (CHD)
Drug: Evolocumab
Drug: Placebo

This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resi...

Active, not recruiting
Hypertension
Drug: Placebo
Drug: lorundrostat Dose 2

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

Trial sponsors

Boehringer Ingelheim logo
Amgen logo
Novartis logo
Integra LifeSciences logo
Kowa logo
M
N
Pfizer logo
Smith & Nephew logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems